Skip to Main Content
Skip Nav Destination

Issues

Pathobiology 2023, Vol. 90, No. 5

Review Article

Pathobiology (2023) 90 (5): 289–311. https://doi.org/10.1159/000528346

Research Article

Pathobiology (2023) 90 (5): 312–321. https://doi.org/10.1159/000530430
Pathobiology (2023) 90 (5): 322–332. https://doi.org/10.1159/000529276
Pathobiology (2023) 90 (5): 333–343. https://doi.org/10.1159/000529723
Pathobiology (2023) 90 (5): 344–355. https://doi.org/10.1159/000530587

Novel Insights from Research Practice

Pathobiology (2023) 90 (5): 356–364. https://doi.org/10.1159/000530429
Established Facts

  • Primary effusion lymphoma (PEL) involves body cavities and usually occurs in HIV-positive individuals.

  • PEL cases occurring in HIV-negative individuals have been reported in organ transplant recipients.

  • Tyrosine kinase inhibitors (TKIs), including dasatinib, alter T-cell function by inhibiting peripheral T-cell migration and altering T-cell trafficking.

  • TKIs, especially dasatinib, have been associated with the development of pleural effusions and pleural effusion-associated lymphomas in patients being treated for chronic myeloid leukemia.

Close Modal

or Create an Account

Close Modal
Close Modal